NCT03507569View on ClinicalTrials.gov

Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

June 22, 2018

Study Completion Date

June 22, 2018

Conditions
Autism Spectrum Disorder
Interventions
DRUG

RO7017773

RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.

OTHER

[11C] Ro15-4513

At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research; Central Middlesex Hospital, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03507569 - Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513 | Biotech Hunter | Biotech Hunter